President Trump has repeatedly promised to carry down prescription drug costs. His Republican Congress says it shares that aim. However tucked contained in the 2026 Consolidated Appropriations Act is a restructuring of the drug market that makes decrease costs much less possible, no more.
How does a Congress that guarantees decrease costs find yourself weakening the bargaining instruments that restrain them? The reply lies much less in ideology than in political incentives. Pharmacy profit managers (PBMs) are opaque intermediaries—and they’re unpopular with figures together with Mark Cuban, who advised Fortune that the way in which they discount over drug costs is absurd, one thing that will by no means occur at the exact same pharmacies shopping for a package deal of Pringles potato-chip merchandise. (Cuban has been working to immediately disrupt the PBM house along with his enterprise, Value Plus Medication.)
If handed into legislation, this act would remodel PBMs from hard-bargaining negotiators into micromanaged directors and weaken the instruments they use to self-discipline drug costs. Focusing on PBMs is less complicated than confronting the suppliers who finally set costs. However in markets the place costs are negotiated, weakening the middleman typically strengthens the companies on the opposite facet of the desk. Right here’s how we received right here.
A long time of rising leverage
For many years, PBMs have relied on two key mechanisms to scale back drug prices. It’s no accident that drug producers—and unbiased pharmacies—have spent years making an attempt to shift political consideration in direction of PBMs. Onerous bargaining works.
The primary mechanism that PBMs use is formulary leverage. Drug producers that need most popular formulary placement—or to keep away from exclusion from protection—should provide higher costs. That leverage for PBMs depends upon a reputable menace: decrease your worth or lose entry to sufferers.
The legislation into account “delinks” PBM compensation from producer rebates in Medicare and requires flat administrative charges, licensed at truthful market worth. It additionally mandates that refunds be handed by means of to well being plan sponsors within the employer-sponsored market. This sounds interesting, however incentives matter. When compensation now not depends upon securing higher phrases, bargaining effort turns into a value heart slightly than a revenue heart. PBMs will nonetheless compete for contracts, however competitors on administrative charges isn’t the identical as competitors on aggressive worth concessions and received’t decrease drug costs.
The second software for PBMs operates downstream. By encouraging sufferers to make use of extra environment friendly, lower-cost pharmacies, PBMs have diminished dishing out prices, enhanced affected person high quality, and strengthened their negotiating leverage upstream. The power to direct quantity towards lower-cost, high-value suppliers creates bargaining energy.
The statute would broaden “any willing pharmacy” necessities, limiting that capability. In nearly each sector, purchasers receive decrease costs by steering quantity towards lower-cost suppliers. When each supplier have to be included on standardized phrases, bargaining energy diminishes and prices are inclined to rise. Broader inclusion could really feel consumer-friendly, however in negotiated markets it typically shifts prices slightly than reduces them.
To make sure, neither software is costless. Formulary exclusions can inconvenience some sufferers, and inspiring sufferers to make use of lower-cost pharmacies can imply switching the place they fill their prescriptions. However each healthcare system faces a selection: tolerate some limits or settle for greater costs throughout the board. Negotiation requires leverage, and leverage requires the flexibility to say no—and to reward lower-cost medication and suppliers with extra enterprise.
The irony is that Congress is weakening cost-control instruments within the title of combating excessive drug prices.
Seniors on Medicare pays the value
For many years, reformers have tried to maneuver American well being care away from cost-plus reimbursement and open-ended fee-for-service medication towards competitors, during which non-public plans negotiate onerous and shift enterprise to these providing higher worth. The brand new PBM regime would transfer in the wrong way: towards regulatory supervision, standardized participation, and diminished discretion.
All members within the prescription drug provide chain deserve scrutiny, however weakening the mechanisms that extract worth concessions won’t decrease drug spending. The extra possible outcomes are beneficial properties for drug corporations and fewer environment friendly pharmacies, and better drug prices. Results will probably be particularly felt by seniors on Medicare and by smaller employers that lack the leverage to offset the legislation’s new constraints.
If lawmakers need decrease drug costs, they need to strengthen aggressive stress, not regulate it into passivity. The politics are simple to grasp. Attacking middlemen polls properly. It permits lawmakers to look robust on costs with out immediately confronting producers. However the economics are much less forgiving. Decrease drug costs require bargaining energy. Congress has simply diminished it. Sufferers and taxpayers will bear the price.
The opinions expressed in Fortune.com commentary items are solely the views of their authors and don’t essentially mirror the opinions and beliefs of Fortune.
